BioMarin Pharmaceutical Inc.
BMRN
$58.14
-$0.87-1.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.36% | 17.97% | 19.14% | 15.83% | 13.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.36% | 17.97% | 19.14% | 15.83% | 13.74% |
| Cost of Revenue | 4.98% | 9.96% | -6.96% | -23.46% | -22.25% |
| Gross Profit | 27.66% | 22.56% | 40.63% | 60.56% | 55.15% |
| SG&A Expenses | -5.83% | -2.04% | 12.54% | 8.00% | 7.07% |
| Depreciation & Amortization | -44.43% | -30.47% | -22.02% | -5.35% | -3.20% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.26% | 0.51% | 10.25% | 8.71% | 9.49% |
| Operating Income | 273.83% | 227.85% | 140.56% | 135.55% | 101.75% |
| Income Before Tax | 184.09% | 187.31% | 158.08% | 176.29% | 228.99% |
| Income Tax Expenses | 371.57% | 449.31% | 1,385.08% | 418.73% | 5,907.16% |
| Earnings from Continuing Operations | 154.99% | 154.62% | 119.21% | 156.61% | 186.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 154.99% | 154.62% | 119.21% | 156.61% | 186.89% |
| EBIT | 273.83% | 227.85% | 140.56% | 135.55% | 101.75% |
| EBITDA | 175.32% | 143.14% | 84.38% | 77.34% | 52.74% |
| EPS Basic | 152.09% | 151.39% | 116.68% | 154.11% | 183.46% |
| Normalized Basic EPS | 251.79% | 226.70% | 120.91% | 123.06% | 103.89% |
| EPS Diluted | 157.25% | 157.15% | 117.91% | 156.99% | 188.83% |
| Normalized Diluted EPS | 252.82% | 223.90% | 117.97% | 121.02% | 102.03% |
| Average Basic Shares Outstanding | 1.15% | 1.17% | 1.21% | 1.26% | 1.34% |
| Average Diluted Shares Outstanding | 1.73% | 2.73% | 2.89% | 2.86% | 3.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |